Discover and read the best of Twitter Threads about #donanemab
Most recents (6)
There's a press release for a new Alzheimer's drug from @EliLillyandCo. My editor @alexmarvar
and I didn't think new coverage did a fair job explaining the results. Here's the jargon free version explaining the #donanemab results from @Being_Patient_
beingpatient.com/eli-lilly-dona…
and I didn't think new coverage did a fair job explaining the results. Here's the jargon free version explaining the #donanemab results from @Being_Patient_
beingpatient.com/eli-lilly-dona…
And of course shout out to @schrag_matthew for back-of-the-napkin calculations of some of the raw CDR-SB scores.
The gist of it all: 
📢Hoy se adelantan los resultados del estudio con nuevo tratamiento anti-amiloide (#Donanemab) con ensayo clínico Fas 3 aparentemente exitoso para fases precoces del #Alzheimer 🧠.
👇
investor.lilly.com/news-releases/…
Resultados interesantes, pero todavía con cautela!
#neurologia #Salud
👇
investor.lilly.com/news-releases/…
Resultados interesantes, pero todavía con cautela!
#neurologia #Salud
En julio en el congreso de la Alzheimer's Association en Amsterdam tendremos más información.
Lo interesante de los resultados es que:
👉 #Donanemab va en la misma línea que #Lecanemab y #Aducanumab (otros anti-amiloide).
👉 Importancia del diagnóstico precoz (pre-demencia).
Lo interesante de los resultados es que:
👉 #Donanemab va en la misma línea que #Lecanemab y #Aducanumab (otros anti-amiloide).
👉 Importancia del diagnóstico precoz (pre-demencia).
Estos estudios van a favor de:
👉 La necesidad de #diagnóstico temprano del #Alzheimer pre-demencia y confirmación diagnóstica mediante #biomarcadores .
👉 Necesidad de apostar por una política de #SaludPública diferente en el campo del #deteriorocognitivo
#Sociedad
👉 La necesidad de #diagnóstico temprano del #Alzheimer pre-demencia y confirmación diagnóstica mediante #biomarcadores .
👉 Necesidad de apostar por una política de #SaludPública diferente en el campo del #deteriorocognitivo
#Sociedad
1/n Good point, Mike. I can use #solanezumab as a case study in selective reporting of RCT trial results which does not serve patient’s interests. Sola was discontinued despite pooled results from 2 ph-3 trials suggesting that ‘mild’ (but not ‘moderate’) stage #Alzheimer patients
2/n may benefit. But a 3rd ph-3 trial in only ‘mild’ AD was clearly negative. Presumed reason was that the Rx did not lower brain amyloid levels enough. Lilly published the MRI findings from these studies looking at brain volume changes. They considered these results important to
3/n report because they noted that “Rates of whole brain volume & ventricular volume changes are sensitive markers of neurodegeneration & used as biomarker outcome measures in trials of potential disease‐modifying therapies.” tinyurl.com/33a7dkh3 They also reported on the
1/n Thoughts on Neurofilament Light (NfL) as a neurodegeneration biomarker. I expect to hear a lot on it in the upcoming #Tofersen Adcom. @US_FDA refers to it as a promising biomarker of neurodegeneration in several diseases at the Relyvrio #ALS approval👇@ProfRobHoward @pash22
2/n This raises an important question- if decreasing NfL levels are associated with clinical benefit outcomes in #ALS, wouldn’t increasing levels associated with worsening clinical outcomes and/or adverse events in #Alzheimer’s be similarly meaningful? Unfortunately these results
3/n have not been published for #aducanumab or #lecanemab. But they have for #donanemab by @LillyPad in phase-2 where accelerated loss of brain volume seen relative to placebo is associated with Increase in NfL levels. Increase in NFL is also significantly associated with faster
1/n 🧵@LillyPad deserves credit for reporting TRAILBLAZER #donanemab results quickly Their blood biomarker results tinyurl.com/bdewaf7b show for the 1st time relationship between change in plasma NfL & brain volume @ProfRobHoward @pash22 @JohnCendpts @AlbertoEspay @Dereklowe
2/n I have long believed that NfL, a marker of neurodegeneration, will track with accelerated brain atrophy in amyloid lowering Rx including #donanemab👇 This indeed appears to be the case. NfL shows significant correlation with change in whole brain volume (R = –0.1710; P =0.03)
3/n Importantly, increase in plasma NfL levels are associated with less slowing in the primary endpoint iADRS scores at week 76 ie worse clinical outcomes (R = –0.182 [95% CI, –0.322 to –0.035];P = 0.02). Caveat; I am always worried if I am interpreting the negative R correctly.
#Donanemab for #Alzheimer, misleadingly spun as positive: “donanemab resulted in a better […] ability to perform activities of daily living than placebo at 76 weeks”. The data suggest otherwise. (1/8)
#EliLilly @NEJM #ADPD2021
nejm.org/doi/full/10.10…
#EliLilly @NEJM #ADPD2021
nejm.org/doi/full/10.10…
(2/8) First off, donanemab accomplished exactly what it was designed for: At 76 weeks, the reduction in the amyloid plaque level as assessed by florbetapir PET was 85.06 centiloids greater in the donanemab group than in the placebo group (−84.13 vs. 0.93 centiloids)
(3/8) However, the primary outcome, the composite iADRS (range, 0 - 144), showed a difference of only 3.20 points in favor of donanemab. While with a p=0.04, the trial was powered to show a 6-point difference. This goal was not reached, as the authors admit in the discussion.
